brigatinib
Selected indexed studies
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. (J Thorac Oncol, 2021) [PMID:34537440]
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. (N Engl J Med, 2018) [PMID:30280657]
- Brigatinib. (, 2012) [PMID:31643841]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. (2023) pubmed
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. (2021) pubmed
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. (2018) pubmed
- Brigatinib. (2012) pubmed
- Brigatinib. (2006) pubmed
- Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors. (2024) pubmed
- Brigatinib for non-small cell lung cancer. (2020) pubmed
- Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. (2022) pubmed
- Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer. (2019) pubmed
- Brigatinib: First Global Approval. (2017) pubmed